FLAMSA-BU regimen: Difference between revisions
Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{AV}} ==Overview== {{PAGENAME}} refers to a regimen consisting of fludarabine, amsacrine, cytarabine (Ara-C) and bu..." |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a regimen consisting of [[fludarabine]], [[amsacrine]], [[cytarabine|cytarabine (Ara-C)]] and [[busulfan]] used as a sequential conditioning therapy for previously untreated patients with high-risk [[myelodysplastic syndrome]] (MDS) or [[acute myelogenous leukemia]] secondary to MDS (sAML).<ref name="pmid21963618">{{cite journal| author=Saure C, Schroeder T, Zohren F, Groten A, Bruns I, Czibere A et al.| title=Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen. | journal=Biol Blood Marrow Transplant | year= 2012 | volume= 18 | issue= 3 | pages= 466-72 | pmid=21963618 | doi=10.1016/j.bbmt.2011.09.006 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21963618 | {{PAGENAME}} refers to a regimen consisting of [[fludarabine]], [[amsacrine]], [[cytarabine|cytarabine (Ara-C)]] and [[busulfan]] used as a sequential conditioning therapy for previously untreated patients with high-risk [[myelodysplastic syndrome]] (MDS) or [[acute myelogenous leukemia]] secondary to MDS (sAML).<ref name="pmid21963618">{{cite journal| author=Saure C, Schroeder T, Zohren F, Groten A, Bruns I, Czibere A et al.| title=Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen. | journal=Biol Blood Marrow Transplant | year= 2012 | volume= 18 | issue= 3 | pages= 466-72 | pmid=21963618 | doi=10.1016/j.bbmt.2011.09.006 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21963618 }} </ref> | ||
==Regimen== | ==Regimen== | ||
| Line 14: | Line 14: | ||
{{chemo|BU|Busulfan}} | {{chemo|BU|Busulfan}} | ||
==Indications== | ==Indications== | ||
Latest revision as of 18:30, 31 March 2015
|
WikiDoc Resources for FLAMSA-BU regimen |
|
Articles |
|---|
|
Most recent articles on FLAMSA-BU regimen Most cited articles on FLAMSA-BU regimen |
|
Media |
|
Powerpoint slides on FLAMSA-BU regimen |
|
Evidence Based Medicine |
|
Cochrane Collaboration on FLAMSA-BU regimen |
|
Clinical Trials |
|
Ongoing Trials on FLAMSA-BU regimen at Clinical Trials.gov Trial results on FLAMSA-BU regimen Clinical Trials on FLAMSA-BU regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on FLAMSA-BU regimen NICE Guidance on FLAMSA-BU regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on FLAMSA-BU regimen Discussion groups on FLAMSA-BU regimen Patient Handouts on FLAMSA-BU regimen Directions to Hospitals Treating FLAMSA-BU regimen Risk calculators and risk factors for FLAMSA-BU regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for FLAMSA-BU regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
FLAMSA-BU regimen refers to a regimen consisting of fludarabine, amsacrine, cytarabine (Ara-C) and busulfan used as a sequential conditioning therapy for previously untreated patients with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia secondary to MDS (sAML).[1]
Regimen
FLFludarabine
AMSAmsacrine
ACytarabine (Ara-C)
BUBusulfan
Indications
- Untreated, high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia secondary to MDS (sAML)[1]
References
- ↑ 1.0 1.1 Saure C, Schroeder T, Zohren F, Groten A, Bruns I, Czibere A; et al. (2012). "Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen". Biol Blood Marrow Transplant. 18 (3): 466–72. doi:10.1016/j.bbmt.2011.09.006. PMID 21963618.